Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

Martin Metzenmacher(Ruhrlandklinik), Wilfried Eberhardt(National Center for Tumor Diseases), Maike de Wit(Florida Hospital Cancer Institute), Martina Jänicke(Iomedico (Germany)), Steffen Dörfel(Onkozentrum Dresden), Stefan Zacharias(Iomedico (Germany)), Jens Uhlig(National Institute of Standards and Technology), Lisa Spring(Iomedico (Germany)), Frank Griesinger(Carl von Ossietzky Universität Oldenburg), Annika Groth(AIO Studien gGmbH), Gregor Zaun(Zero to Three), Jens Kern(Klinikum Würzburg Mitte), Ulrich Kaiser(University of Applied Sciences Landshut), Anja Kaiser‐Osterhues(Iomedico (Germany)), B. Güldenzoph(Praxis für Hämatologie und Onkologie), Lothar Müller, Corinna Elender(Klinikum Dortmund), A. Hipper(AIO Studien gGmbH), Horst-Dieter Hummel(Comprehensive Cancer Center Mainfranken), Michael Thomas, Harald Schäfer, Martin Sebastian(Goethe University Frankfurt)
European Respiratory Journal
September 30, 2022
10.1183/13993003.01336-2022
Cited by 17

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k